Allogene Therapeutics Reports Q4 Earnings

Biotech firm exceeds Wall Street expectations despite $38.8 million loss

Mar. 12, 2026 at 8:23pm

Got story updates? Submit your updates here. ›

Allogene Therapeutics Inc., a biopharmaceutical company based in South San Francisco, California, reported a loss of $38.8 million in its fourth quarter. However, the company's results exceeded Wall Street expectations, with a loss of 17 cents per share compared to the average analyst estimate of a 25 cent per share loss.

Why it matters

As a clinical-stage biotechnology company focused on developing allogeneic CAR T (AlloCAR T) therapies for cancer, Allogene's financial performance is closely watched by investors and industry analysts. The company's ability to manage costs and meet or exceed earnings expectations is seen as an indicator of its progress in advancing its pipeline of experimental cancer treatments.

The details

Allogene Therapeutics reported a net loss of $38.8 million, or 17 cents per share, for the fourth quarter. This was better than the average analyst estimate of a 25 cent per share loss. For the full year, the company reported a narrowed loss of $190.9 million, or 87 cents per share.

  • Allogene Therapeutics reported its Q4 and full-year 2025 financial results on March 12, 2026.

The players

Allogene Therapeutics Inc.

A clinical-stage biotechnology company focused on developing allogeneic CAR T (AlloCAR T) therapies for cancer.

Got photos? Submit your photos here. ›

The takeaway

Allogene Therapeutics' ability to exceed Wall Street's expectations for its Q4 earnings, despite reporting an overall loss, suggests the company is making progress in managing costs as it advances its pipeline of experimental cancer treatments.